AVAXIM

also known as TRIMOVAX

Developed for: hepatitis A virus infection · measles · mumps infectious disease · rubella
Investigated by: National Institute of Allergy and Infectious Diseases (NIAID) · Sanofi Pasteur, a Sanofi Company

today NCT03917654 · Ph 2 NCT00313950 · Ph 4

200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 21 trial
Phase 2	NCT03917654	Apr 2019 → Jul 2021	malaria	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 41 trial
Phase 4	NCT00313950	Sep 2006 → Dec 2009	hepatitis A virus infection, measles, mumps infectious disease, rubella	Sanofi Pasteur, a Sanofi Company	Completed	No outcome recorded

Also used as a comparator or background therapy in 1 trial

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 2	NCT01064141 Background	Jan 2010 → Sep 2012	Dengue hemorrhagic fever	Sanofi	Completed	No outcome recorded

Every value below carries the sentence it was read from. 3 sources stand behind the page.

Field	Value	Cited text
Known as	AVAXIM	“Immunogenicity and Safety of AVAXIM™ 80U-Pediatric Administered Alone or Concomitantly With TRIMOVAX™ in 12-13 Months Old Healthy Hepatitis A Seronegative Turkish Children” NCT00313950 ↗ 1 NCT03917654 ↗
Known as	TRIMOVAX	“Immunogenicity and Safety of AVAXIM™ 80U-Pediatric Administered Alone or Concomitantly With TRIMOVAX™ in 12-13 Months Old Healthy Hepatitis A Seronegative Turkish Children” NCT00313950 ↗ 2 “TRIMOVAX®” NCT01064141 ↗ “TRIMOVAX®” NCT01064141 ↗
Modality	Vaccine	“Hepatitis A Vaccine Inactivated” NCT03917654 ↗